Aprea Therapeutics updates patent portfolio to 28 issued patents
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs
August 28, 2026 8:15 AM EDTCompany Strengthens Global Intellectual Property Portfolio with 28 Issued and 30 Pending Patents
DOYLESTOWN, Pa., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (Aprea, or the Company), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today provided an update on its existing patent portfolio.
Our expanding patent portfolio reflects Apreas commitment to innovation and building a differentiated leadership position in precision medicine, said Oren Gilad, Ph.D., President and Chief Executive Officer of Aprea. A strong global intellectual property portfolio is a... More
